ArticleBMC pulmonary medicine2025
A noval identification of 4 systemic sclerosis - interstitial lung disease subgroups using principal component analysis-based cluster analysis.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unlocking multi-institutional insights into disease progression with PEAL as a lossless, one-shot federated learning solution.NPJ digital medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveInterstitial lung disease (ILD) is a common and serious complication of systemic sclerosis (SSc). It is usually classified by histologic type, but this classification may not fully reflect the clinical phenotypic variation. This study aimed to examine clinical features and aggregate patients with SSc-ILD based on patients' clinical manifestations, High-resolution computed tomography (HRCT) features and specific antibody expression to achieve precise treatment of SSc-ILD with early identification of complications.
methodsThis study included 103 patients with SSc-ILD. A cluster analysis was performed based on five clinical and serological variables to identify subgroups of patients. The survival rates between obtained clusters and risk factors affecting prognosis were also compared.
resultFour clusters were identified in this study: Cluster 1 (n = 23) represented the lymphocytic interstitial pneumonia (LIP) group with LIP as the predominant HRCT characteristic. Cluster 2 (n = 23) was the worst prognosis group, with the highest Warrick score as well as the highest mortality rate. Cluster 3 (n = 20) with all patients having a negative anti-SCL-70 antibody response. Cluster 4 (n = 28) with all patients were positive for the anti-SCL-70 antibody. It was found that albumin was a protective factor for the prognosis of patients with SSC-ILD patients (p = 0.018), whereas age (p = 0.036) and IgM (p = 0.040) were risk factors.
conclusionThe results of our cluster analysis indicated that based solely on histologic typing, may not be capturing the full heterogeneity of SSc-ILD patients. In order to identify homogeneous patient groups with a specific prognosis, HRCT features and antibody profiles should be taken into consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.